1023. Deputy Ken O'Flynn asked the Minister for Health what consideration has been given to the equity implications of high out-of-pocket costs for GLP-1 receptor agonist medicines; whether the Department has examined the risk of access being determined by ability to pay rather than clinical need; and if she will outline any measures under consideration to address this issue. [7679/26]

Summary

1023. Deputy Ken O'Flynn asked the Minister for Health what consideration has been given to the equity implications of high out-of-pocket costs for GLP-1 receptor agonist medicines; whether the Department has examined the risk of access being determined by ability to pay rather than clinical need; and if she will outline any measures under consideration to address this issue. [7679/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 4 February 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.